Market closedNon-fractional

Avita Therapeutics/RCEL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Avita Therapeutics

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Ticker

RCEL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Valencia, United States

Employees

207

RCEL Metrics

BasicAdvanced
$209M
Market cap
-
P/E ratio
-$1.76
EPS
1.42
Beta
-
Dividend rate
$209M
1.42
7.249
6.347
134.585
134.585
-19.99%
-32.80%
-81.39%
4.05
6.38
6.49
-3.935
35.44%
66.69%

What the Analysts think about RCEL

Analyst Ratings

Majority rating from 8 analysts.
Buy

RCEL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-167.56% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$11M
-21.28%
Net income
-$19M
165.71%
Profit margin
-167.56%
237.55%

RCEL Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 54.27%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.41
-$0.34
-$0.28
-$0.73
-
Expected
-$0.32
-$0.44
-$0.37
-$0.47
-$0.52
Surprise
26.39%
-23.42%
-25.21%
54.27%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Avita Therapeutics stock?

Avita Therapeutics (RCEL) has a market cap of $209M as of July 06, 2024.

What is the P/E ratio for Avita Therapeutics stock?

The price to earnings (P/E) ratio for Avita Therapeutics (RCEL) stock is 0 as of July 06, 2024.

Does Avita Therapeutics stock pay dividends?

No, Avita Therapeutics (RCEL) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Avita Therapeutics dividend payment date?

Avita Therapeutics (RCEL) stock does not pay dividends to its shareholders.

What is the beta indicator for Avita Therapeutics?

Avita Therapeutics (RCEL) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Avita Therapeutics stock

Buy or sell Avita Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing